Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

2349 - The safety assessment of crizotinib and alectinib from real world data of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L).

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Kei Kunimasa

Citation

Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260

Authors

K. Kunimasa1, K. Ito2, T. Yamanaka3, D. Fujimoto4, M. Mori5, K. Maeno6, K. Tomomatsu7, A. Tamura8, H. Tanaka9, S. Watanabe10, S. Teraoka11, O. Hataji12, K. Suzuki13, S. Hontsu14, S. Hara15, A. Bessho16, A. Kubo17, M. Okuno18, K. Nakagawa19, N. Yamamoto20

Author affiliations

  • 1 Thoracic Oncology, Osaka International Cancer Institute, 5418567 - Osaka/JP
  • 2 Respiratory Center, Matsusaka City Hospital, 515-8544 - Matsusaka/JP
  • 3 Department Of Biostatistics, Yokohama City University Hospital, 236-004 - Yokohama/JP
  • 4 Respiratory Medicine, Kobe City Medical Center General Hospital, 650-0047 - Kobe/JP
  • 5 Department Of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, 560-8552 - Toyonaka/JP
  • 6 Department Of Respiratory Medicine, Allergy And Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, 467-8601 - Aichi/JP
  • 7 Division Of Pulmonary Medicine, Department Of Medicine, Tokai University School of Medicine, Kanagawa/JP
  • 8 Department Of Respiratory Diseases, National Hospital Organization Tokyo National Hospital, Tokyo/JP
  • 9 Department Of Internal Medicine, Niigata Cancer Center Hospital, 951-8566 - Niigata/JP
  • 10 Department Of Respiratory Medicine And Infectious Diseases, Niigata UniversityNiigata University Graduate School of Medical and Dental Sciences, 951-8510 - Niigata/JP
  • 11 Department Of Pulmonary Medicine And Oncology, Wakayama Medical University Hospital, Wakayama/JP
  • 12 Respiratory Center, Matsusaka Municipal Hospital, 515-8544 - Matsusaka/JP
  • 13 Internal Medicine, Toyama prefectural central hospital, Toyama/JP
  • 14 Department Of Respiratory Medicine, Nara Medical University, 634-8522 - Nara/JP
  • 15 Respiratory Division, Department Of Internal Medicine, Itami City Hospital, Hyogo/JP
  • 16 Department Of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama/JP
  • 17 Division Of Respiratory Medicine And Allergology, Aichi Medical University School of Medicine, Aichi/JP
  • 18 Department Of Respiratory Medicine, Okazaki City Hospital, Aichi/JP
  • 19 Medical Oncology, Kindai University School of Medicine, 577-8502 - Osaka/JP
  • 20 Department Of Pulmonary Medicine And Oncology, Wakayama Medical University, Wakayama/JP

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2349

Background

Previous clinical trials demonstrated that alectinib (ALEC) produced fewer adverse events compared to crizotinib (CRZ). Data regarding adverse events (AE) in clinical practice, however, is limited. We reviewed ALK-rearranged NSCLC patients treated with crizotinib or alectinib in institutions of the West Japan Oncology Group, and the safety of CRZ and ALEC were evaluated using the real-world data.

Methods

We reviewed the clinical data of ALK-rearranged NSCLC patients who received CRZ or ALEC between May 2012 and Dec 2016. Patients were divided into two groups, the CRZ, or the ALEC group. To evaluate the safety of each ALK-inhibitor, we compared the AEs between the CRZ and the ALEC groups.

Results

Of 864 patients enrolled from 61 institutions, 840 patients were analyzed. Median age was 61 (range, 20-94); 56% were female; and 95% had adenocarcinoma. There was no significant difference in the frequencies of ILD, renal dysfunction, and digestive dysfunction between the CRZ and the ALEC groups.(p = 0.905, p = 0.7208, p = 0.1735) Meanwhile, liver dysfunction was significantly more frequent in the CRZ group compared to the ALEC group.(50.7% in CRZ group vs. 29.1% in ALEC group, p = 0.0313) In adverse events of grade 3 or more, liver dysfunction remained significantly different in frequency between the two groups.(13.3% in CRZ vs. 3.9% in ALEC, p < 0.0001) Discontinuation due to adverse event was shown to be in 21.1% in the CRZ group, and 6.9% in the ALEC group.(p = 0.0656) Seventy-nine patients received alectinib therapy after the discontinuation of crizotinib due to an adverse event, with progression-free survival (PFS) of 24.8 months.

Conclusions

In clinical practice, the patients treated with CRZ exhibited a trend to discontinue CRZ at a higher rate due to AE compared to the ALEC group. The PFS of patients treated with ALEC, even in the patients who experience AE due to CRZ, was more than 2 years.

Clinical trial identification

UMIN000028605.

Editorial acknowledgement

Legal entity responsible for the study

Nobuyuki Yamamoto.

Funding

Pfizer.

Disclosure

K. Ito: Honoraria (self): Pfizer; Honoraria (self), Research grant / Funding (institution): Boehringer Ingelheim; Speaker Bureau / Expert testimony: Chugai; Honoraria (self): Eli Lilly; Honoraria (self): MSD; Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Kyorin; Research grant / Funding (institution): Daiichi-Sankyo. T. Yamanaka: Honoraria (self), Research grant / Funding (self): Takeda; Honoraria (self): Chugai; Honoraria (self), Research grant / Funding (self): Taiho; Honoraria (self): Boehringer Ingelheim; Advisory / Consultancy: Giiead Sciences; Advisory / Consultancy: Bayer. D. Fujimoto: Honoraria (self), Research grant / Funding (self): AstraZeneca; Honoraria (self): Ono Pharmaceutical; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Taiho Pharmaceutical Co; Honoraria (self): Chugai Pharmaceutical Co; Honoraria (self): MSD KK; Honoraria (self): Boehringer Ingelheim Japan Inc; Honoraria (self): Eli Lilly Japan KK,. M. Mori: Honoraria (institution), Speaker Bureau / Expert testimony: Chugai. H. Tanaka: Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self), Research grant / Funding (institution): Eli Lilly; Honoraria (self), Research grant / Funding (institution): MSD; Honoraria (self), Research grant / Funding (institution): Taiho pharmaceuticals; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self): Novartis; Honoraria (self), Research grant / Funding (institution): Ono pharmaceuticals; Honoraria (self), Research grant / Funding (institution): Chugai pharmaceuticals; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Takeda pharmaceuticals; Research grant / Funding (institution): Merck Serono. S. Teraoka: Honoraria (self): Chugai Pharmaceutical. O. Hataji: Honoraria (self): Chugai; Honoraria (self): Pfizer; Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self), Research grant / Funding (institution): Boerhringer Ingelheim; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Daiichi-Sankyo; Honoraria (self), Research grant / Funding (institution): Kyorin; Honoraria (self): Eli Lilly. A. Bessho: Honoraria (self), Speaker Bureau / Expert testimony: Chugai Pharmaceutical Co., Ltd.; Honoraria (self), Speaker Bureau / Expert testimony, Research grant / Funding (institution): Pfizer Japan Inc. A. Kubo: Honoraria (self), Research grant / Funding (self): Boehringer Ingerheim; Honoraria (self), Research grant / Funding (self): Chugai; Honoraria (self), Research grant / Funding (self): Eli Lilly; Honoraria (self): MSD; Honoraria (self), Research grant / Funding (self): Novartis; Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (self): Ono Pharma. K. Nakagawa: Honoraria (self), Advisory / Consultancy: Astellas Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Takeda Pharmaceutical; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Chugai; Honoraria (self), Research grant / Funding (institution): MSD; Honoraria (self), Research grant / Funding (institution): Eli Lilly; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Boehringer Ingelheim; Honoraria (self), Research grant / Funding (institution): Daiichi Sankyo; Honoraria (self), Research grant / Funding (institution): Novartis Pharma; Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Pfizer Japan; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb Company; Honoraria (self): KYORIN Pharmaceutical; Honoraria (self): MEDICUS SHUPPAN,Publishers; Honoraria (self): Thermo Fisher Scientific K.K; Honoraria (self): Nichi-Iko Pharmaceutical ; Honoraria (self): Hisamitsu Pharmaceutical; Research grant / Funding (institution): Eisai Co; Research grant / Funding (institution): PAREXEL International Corp. N. Yamamoto: Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self), Research grant / Funding (institution): Chugai. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.